Перспективы изотретиноина в терапии торпидных форм акне

Дворянкова Е.В., Голембиовская И.В., Сакания Л.Р., Корсунская И.М. Перспективы изотретиноина в терапии торпидных форм акне. Consilium Medicum. Дерматология (Прил.). 2015; 3: 16–19.

________________________________________________

Dvoryankova E.V., Golembiovskaya I.V., Sakaniya L.R., Korsunskaya I.M. Prospects of isotretinoin in the treatment of torpid forms of acne. Consilium Medicum. Dermatology (Suppl.). 2015; 3: 16–19.

Читать PDF

Аннотация

В работе приводятся основные сведения о применении системных ретиноидов в терапии тяжелых форм акне, отмечены основные негативные эффекты при назначении данной группы препаратов. Описаны механизмы действия изотретиноина на патогенез акне. Также представлены собственные наблюдения, позволяющие достигнуть кумулятивной дозы препарата с наименьшими отрицательными клиническими проявлениями.
Ключевые слова: изотретиноин, акне, тяжелые формы.

________________________________________________

The paper presents basic information about the use of systemic retinoids in the treatment of severe acne, the main adverse effects observed in the appointment of this group of drugs. The mechanisms of action of isotretinoin in the pathogenesis of acne. Also presented his own observations, allowing to achieve a cumulative dose of the drug with the least adverse clinical manifestations.

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Patton TJ, Zirwas MJ, Wolverton SE. Systemic retinoids. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy. 2nd ed. Philadelphia: Saunders-Elsevier, 2007; p. 275–300.
2. Cryulnik AA, Viola KV, Gewirtzman AJ et al. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int J Dermatol 2012; 51: 1123–30.
3. Stainforth JM, Layton AM, Taylor JP et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993; 129: 297–301.
4. Lehucher CD, De la Salmoniere P et al. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999; 198: 278–83.
5. Strauss JS, Rapini RP, Shalita AR et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10 (3): 490–6.
6. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–9.
7. Strauss JS, Krowchuk DP, Leyden JJ et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56 (4): 651–63.
8. White GM, Chen W. Recurrence rates after first course of isotretinoin. Arch Dermatol 1998; 134: 376–78.
9. Layton A. The use of isotretinoin in acne. Dermatoendocrinology 2009; 1 (3): 162–9.
10. Nelson AM, Zhao W, Gilliland KL et al. Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells. J Clin Investig 2008; 118: 1468–78.
11. Ward A, Brogden RN, Heel RC et al. Isotretinoin: a review of its pharmacologic properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984; 28: 6–37.
12. Dispenza MC, Wolpert EB, Gilliland KL et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012; 132: 2198–205.
13. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–9.
14. Кочергин Н.А., Самгин М.А., Монахов С.А., Игнатьев Д. Дерматологический индекс акне. Эстетическая медицина. 2004; 3 (1): 62–5. / Kochergin N.A., Samgin M.A., Monakhov S.A., Ignat'ev D. Dermatologicheskii indeks akne. Esteticheskaia meditsina. 2004; 3 (1): 62–5. [in Russian]

________________________________________________

1. Patton TJ, Zirwas MJ, Wolverton SE. Systemic retinoids. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy. 2nd ed. Philadelphia: Saunders-Elsevier, 2007; p. 275–300.
2. Cryulnik AA, Viola KV, Gewirtzman AJ et al. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int J Dermatol 2012; 51: 1123–30.
3. Stainforth JM, Layton AM, Taylor JP et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993; 129: 297–301.
4. Lehucher CD, De la Salmoniere P et al. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999; 198: 278–83.
5. Strauss JS, Rapini RP, Shalita AR et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10 (3): 490–6.
6. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–9.
7. Strauss JS, Krowchuk DP, Leyden JJ et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56 (4): 651–63.
8. White GM, Chen W. Recurrence rates after first course of isotretinoin. Arch Dermatol 1998; 134: 376–78.
9. Layton A. The use of isotretinoin in acne. Dermatoendocrinology 2009; 1 (3): 162–9.
10. Nelson AM, Zhao W, Gilliland KL et al. Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells. J Clin Investig 2008; 118: 1468–78.
11. Ward A, Brogden RN, Heel RC et al. Isotretinoin: a review of its pharmacologic properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984; 28: 6–37.
12. Dispenza MC, Wolpert EB, Gilliland KL et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012; 132: 2198–205.
13. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–9.
14. Kochergin N.A., Samgin M.A., Monakhov S.A., Ignat'ev D. Dermatologicheskii indeks akne. Esteticheskaia meditsina. 2004; 3 (1): 62–5. [in Russian]

Авторы

Е.В.Дворянкова1, И.В.Голембиовская2, Л.Р.Сакания1, И.М.Корсунская*1
1. ФГБУН Центр теоретических проблем физико-химической фармакологии РАН. 119991, Россия, Москва, Ленинский пр-т, д. 38а, корп. 1;
2. ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6
*marykor@bk.ru

________________________________________________

E.V.Dvoryankova1, I.V.Golembiovskaya2, L.R.Sakaniya1, I.M.Korsunskaya*1
1. Center for Theoretical Problems of Physicochemical Pharmacology. 119991, Russian Federation, Moscow, Leninskiy pr-t, d. 38a, korp. 1;
2. People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 6
*marykor@bk.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.